Browse the evidence

Semaglutide (Wegovy) has demonstrated unprecedented efficacy in weight reduction, glycaemic control, and cardiovascular protection.

Semaglutide may be a highly effective treatment option for obesity and type 2 diabetes.

Achieving ≥ 5% total weight loss (TWL) is associated with a higher risk ratio (RR) of type 2 diabetes remission (RR = 7.88).

Practitioners should encourage patients to aim for at least 5% weight loss to improve diabetes remission rates.

Achieving ≥ 5% TWL is associated with a higher RR of hypertension remission (RR = 2.23).

Encouraging weight loss of at least 5% may help patients achieve better blood pressure control.

Achieving ≥ 5% TWL leads to significant mean differences in metabolic risk factors including HbA1c, fasting plasma glucose, and blood pressure.

Weight loss of at least 5% can lead to significant improvements in key metabolic health indicators.

Subcutaneous semaglutide 0.5 mg and subcutaneous liraglutide 3 mg are effective treatments for reducing weight among people with obesity in a real-world scenario after 3 months.

Both semaglutide and liraglutide can be considered effective options for weight management in clinical practice.

Weight reduction starting at 5% body weight confers metabolic protection, such as improved hypertension and dysglycemia.

Encouraging patients to achieve at least a 5% weight loss can improve their metabolic health.

Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) provide potent weight reduction among persons with overweight/obesity and show cardiovascular benefits.

GLP-1 RAs may be considered as a therapeutic option for weight management in patients with HIV and obesity.

Semaglutide is endorsed as a secondary treatment for improving glycemic control in type 2 diabetes mellitus (T2DM).

Practitioners can consider semaglutide as a secondary option for patients with T2DM to improve blood sugar control.

Semaglutide is being investigated for its potential in combating obesity.

Practitioners should stay informed about the potential use of semaglutide for obesity management.

Semaglutide can help regulate blood sugar levels and decrease long-term health complications related to diabetes.

Practitioners can use semaglutide to manage blood sugar levels and reduce diabetes-related complications.

Intermittent fasting has cardiometabolic effects in persons with prediabetes and type 2 diabetes.

Healthcare providers may consider intermittent fasting as a potential dietary intervention for patients with prediabetes and type 2 diabetes.

Nutritional deficiencies, particularly in vitamins and minerals, necessitate dietary counseling and supplementation for post-weight-loss patients.

Dietary counseling should be integrated into post-weight-loss care.

Semaglutide consistently produces substantial reductions in body weight and visceral fat, accompanied by improvements in blood pressure, glycemic control, inflammatory markers, and hepatic steatosis.

Practitioners can expect significant improvements in metabolic health markers with semaglutide use.

SELECT demonstrated a significant reduction in major adverse cardiovascular events in adults with overweight or obesity and established atherosclerotic cardiovascular disease, independent of diabetes status.

Semaglutide may significantly lower the risk of cardiovascular events in at-risk populations.

The use of weight reduction medications as an adjunct therapy alongside dietary, exercise, and behavioral interventions is clearly described in current and future guidelines of the German Obesity Society.

Practitioners should consider weight reduction medications as part of a comprehensive treatment plan.

Liraglutide reduced total body mass and lowered absolute and percent android fat over 18 days.

Liraglutide may be effective for weight loss in individuals with type 2 diabetes.

Bariatric surgery is the most durable and effective treatment for severe obesity.

Clinicians should consider bariatric surgery for patients with severe obesity.

Weight loss in individuals with obesity can improve metabolic outcomes.

Practitioners should recognize that while weight loss may improve metabolic health, its effects on mortality are uncertain.

Obesity is a significant modifiable risk factor for atrial fibrillation (AF).

Practitioners should focus on managing obesity to reduce the risk of AF.

The Atrial Fibrillation Better Care pathway emphasizes lifestyle modifications and weight loss strategies for managing AF in obesity.

Implementing lifestyle changes is essential for managing AF in obese patients.

FDA-approved medications such as orlistat, phentermine/topiramate, bupropion/naltrexone, and liraglutide have significantly improved weight-loss outcomes.

Practitioners can consider these medications as effective options for weight management.

Semaglutide and tirzepatide achieve weight-loss outcomes comparable to bariatric surgery.

These medications may be considered as alternatives to surgical weight loss options.

Clinical practice guidelines have been updated to reflect the use of glucose-lowering medications for cardiometabolic, renal, and weight goals.

Healthcare providers should integrate these updated guidelines into practice.

GLP-1 agonists are approved for weight loss in addition to their original approval for type 2 diabetes.

Healthcare providers should consider GLP-1 agonists for patients needing weight loss support.